TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is an increasingly common condition, strongly associated with the metabolic syndrome, that can lead to progressive hepatic fibrosis, cirrhosis and hepatic failure. Subtle inter-patient genetic variation and environmental factors combine to determine variation in disease progression. A common non-synonymous polymorphism in TM6SF2 (rs58542926 c.449 C>T, p.Glu167Lys) was recently associated with increased hepatic triglyceride content, but whether this variant promotes clinically relevant hepatic fibrosis is unknown. Here we confirm that TM6SF2 minor allele carriage is associated with NAFLD and is causally related to a previously reported chromosome 19 GWAS signal that was ascribed to the gene NCAN . Furthermore, using two histologically characterized cohorts encompassing steatosis, steatohepatitis, fibrosis and cirrhosis (combined n =1,074), we demonstrate a new association, independent of potential confounding factors (age, BMI, type 2 diabetes mellitus and PNPLA3 rs738409 genotype), with advanced hepatic fibrosis/cirrhosis. These findings establish new and important clinical relevance to TM6SF2 in NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The rs58542926 minor allele of transmembrane 6 superfamily member 2 (TM6SF2) is also reportedly associated with MASLD and sometimes MASH (134, 140-142).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [140]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Furthermore, the splice variant rs72613567 in the Hydroxysteroid 17-beta Dehydrogenase 13 (HSD17B13) gene has been identified as protective against MASH, with HSD17B13 potentially contributing to MASH fibrosis by promoting pyrimidine catabolism (134, 140-142).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [140]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Primary carcinoma of the liver.A study of 100 cases among 48,900 necropsies
Edmondson, H. A., & Steiner, P. E. (1954) · Cancer · doi:10.1002/1097-0142(195405)7:3<462::aid-cncr2820070308>3.0.co;2-e · Cited by 2,772
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Purcell, S., Cherny, S. S., & Sham, P. C. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.1.149 · Cited by 2,057
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747
Self-citation
Cited by
Items 401–500 of 623
Interleukin-2 receptor alpha as a biomarker for nonalcoholic fatty liver disease diagnosis
Kao, W., Lin, Y., Chang, I., Chen, C., Tang, J., Chang, C., Chang, Y., & Wang, W. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000469 · Cited by 13
Bilić-Čurčić, I., Berković, M. C., Virović-Jukić, L., & Mrzljak, A. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i1.80 · Cited by 14
Balcar, L., Semmler, G., Oberkofler, H., Zandanell, S., Straßer, M., Datz, L., Niederseer, D., Feldman, A., Stickel, F., Datz, C., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.06.015 · Cited by 13
Kim, D., Shah, M., Kim, J. H., Kim, J., Baek, Y.-H., Jeong, J., Han, S., Lee, Y. S., Park, G., Cho, J.-H., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000805 · Cited by 9
“…domain-containing 3 ( PNPLA3 ) and transmembrane 6 superfamily member 2 ( TM6SF2 ) have been associated with MASH and HCC. [3] The T allele of TM6SF2 is associated with MASLD and the risk of advanced liver fibrosis, [4] whereas the G allele of PNPLA3 is associated with hepatic fat accumulation.”
Chang, H., Liang, S.-X., Li, Z.-Y., Li, R.-N., Zhu, H.-B., He, M., Cui, H., He, J., Li, Y., Wang, J.-R., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06670-5 · Cited by 11
“A common non-synonymous polymorphism in TM6SF2 rs58542926 was recently associated with increased hepatic triglyceride content, but also promotes clinically relevant hepatic fibrosis [43, 44].”
Liu, Y. (2025) · Liver Cancer · doi:10.1159/000550163 · Cited by 17
Self-citationCurrent approaches to diagnosing and treating nonalcoholic fatty liver disease
Никонов, Е. Л., & Va, A. (2018) · Russian Journal of Preventive Medicine · doi:10.17116/profmed201831262 · Cited by 24
James, G., Reisberg, S., Lepik, K., Galwey, N. W., Avillach, P., Kolberg, L., Mägi, R., Esko, T., Alexander, M., Waterworth, D. M., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215026 · Cited by 10
Köpp, J., Fleßa, S., Lieb, W., Markus, M. R. P., Teumer, A., Homuth, G., Wallaschofski, H., Marschall, P., Völzke, H., & Baumeister, S. E. (2015) · BMC Health Services Research · doi:10.1186/s12913-016-1289-6 · Cited by 9
“Recently, TM6SF2 rs5842926 has been associated with liver fat fraction, severity of steatosis, and fibrosis [10, 11].”
BackgroundPerturbation of TM6SF2 Expression Alters Lipid Metabolism in a Human Liver Cell Line
Pant, A., Chen, Y., Kuppa, A., Du, X., Halligan, B. D., & Speliotes, E. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189758 · Cited by 8
The role of nutrition in non-alcoholic fatty liver disease treatment in obese children.
Guimber, D., Debray, D., Bocquet, A., Briend, A., Chouraqui, J.-P., Darmaun, D., Feillet, F., Frelut, M., Hankard, R., Lapillonne, A., et al. (2022) · PubMed · doi:10.1016/j.arcped.2021.09.009 · Cited by 10
Fassio, E., Barreyro, F. J., Pérez, M. S., Dávila, D., Landeira, G., Gualano, G., & Ruffillo, G. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i2.354 · Cited by 14
Apolipoprotein A5 gene polymorphisms are associated with non-alcoholic fatty liver disease
Xu, Y., Lu, L., Liu, S., Du, S.-X., Zhu, H., Dong, Q., & Xin, Y. (2018) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2018.04.004 · Cited by 9
Peloso, A., Tihy, M., Moeckli, B., Rubbia‐Brandt, L., & Toso, C. (2022) · Nutrients · doi:10.3390/nu14245340 · Cited by 9
“For this, TM6SF2 inactivation has been positively correlated with the histological gravity of steatosis and all the elements of the NAFLD activity score [36,37].”
BackgroundGenomic Signatures of MASLD: How Genomics Is Redefining Our Understanding of Metabolic Liver Disease
Saliba‐Gustafsson, P., Härdfeldt, J., Pedrelli, M., & Parini, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210881 · Cited by 10
“TM6SF2 (Transmembrane 6 Superfamily Member 2) is another key gene, with the rs58542926 C>T variant linked to higher liver fat accumulation by influencing the secretion of very low-density lipoprotein (VLDL) from hepatocytes [50–52] as well as liver fibrosis [53].”
Aboraia, G. Y., Abdelsameea, E., Taie, D. T., Elshaarawy, O., Bayomy, N. R., Mostafa, R., Alsharnoby, A. A., & Diab, K. (2022) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2022.119265 · Cited by 8
“Other studies, however, demonstrated that the presence of the TM6SF2 variant did not appear to be associated with a further increased risk of developing HCC [22].”
ResultPathogenesis of NAFLD and NASH
Maher, J. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-20538-0_4 · Cited by 10
Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease
Iruzubieta, P., González, M., Cabezas, J., Arias-Loste, M. T., & Crespo, J. (2018) · InTech eBooks · doi:10.5772/intechopen.72668 · Cited by 10
Saiman, Y., Hooks, R., & Carr, R. M. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00539-5 · Cited by 9
Zhou, Z., Sang, L., Wang, J., Song, L., Zhu, L., Wang, Y., Xiao, J., & Lian, Y. (2021) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2021.112986 · Cited by 8
Myeloid TM6SF2 Deficiency Inhibits Atherosclerosis
Zhu, W., Liang, W., Lu, H., Chang, L., Zhang, J., Chen, Y. E., & Guo, Y. (2022) · Cells · doi:10.3390/cells11182877 · Cited by 9
Genetic Markers Predisposing to Nonalcoholic Steatohepatitis
Sohal, A., Chaudhry, H., & Kowdley, K. V. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.006 · Cited by 10
Genetic Aspects of Non-Alcoholic Fatty Liver Disease
Bogomolov, P., Kokina, K. Y., Mayorov, A. Y., & Mishina, E. Е. (2019) · Вопросы современной педиатрии · doi:10.15690/vsp.v17i6.1974 · Cited by 14
“заболевания печени с формированием фиброза [33].”
Epidemiology, Natural History, and Evaluation of Nonalcoholic Fatty Liver Disease
Anstee, Q. M., & Day, C. P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-37591-7.00026-4 · Cited by 10
Self-citationNault, J., & Nahon, P. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.001 · Cited by 9
“Subsequent validation in patients with NASH confirmed its effect on fibrosis progression and suggested a possible impact on HCC development, although issues of low power of analyses with insufficient sample size must be acknowledged [17].”
BackgroundNon‐alcoholic fatty liver disease
Caldwell, S. H., & Argo, C. K. (2016) · Wiley eBooks · doi:10.1002/9781118924938.ch1 · Cited by 11
The future of diagnosing NASH - could a simple blood test be the key?
Francque, S., & Vonghia, L. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1374851 · Cited by 8
Self-citationNonalcoholic Fatty Liver Disease
Boyle, M., & Anstee, Q. M. (2019) · Wiley eBooks · doi:10.1002/9781119211419.ch35 · Cited by 8
Self-citationTINIAKOS, D. G., Anstee, Q. M., Brunt, E. M., & Burt, A. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8228-3.00005-3 · Cited by 9
Self-citationExploring the impact of lipid droplets on the evolution and progress of hepatocarcinoma
Maurotti, S., Geirola, N., Frosina, M., Mirarchi, A., Scionti, F., Mare, R., Montalcini, T., Pujia, A., & Tirinato, L. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1404006 · Cited by 9
Moonlisarn, K., Somnark, P., Boonkaew, B., Bunchorntavakul, C., & Tangkijvanich, P. (2024) · Genes · doi:10.3390/genes15111370 · Cited by 9
“For example, the TM6SF2 SNP could affect fibrosis progression in Western patients but did not affect advanced fibrosis or cirrhosis in Asian subjects [33,34].”
Gene-based therapies for steatotic liver disease
Iakovleva, V., & de Jong, Y. P. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.024 · Cited by 9
Torre, P., Motta, B. M., Sarcina, T., Festa, M., Masarone, M., & Persico, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178426 · Cited by 8
“Single SNP analysis supports previous literature: PNPLA3 as a major driver of liver injury, independently of obesity [18], and TM6SF2 impacting lipid levels [19].”
Du, S.-X., Liao, S., Liu, S., & Xin, Y. (2019) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2018.00055 · Cited by 7
Liu, S., Murakami, E., Nakahara, T., Ohya, K., Teraoka, Y., Makokha, G. N., Uchida, T., Morio, K., Fujino, H., Ono, A., et al. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11654 · Cited by 9
“incidence of NAFLD and with fibrosis stage (10-13).”
BackgroundHCC in metabolic syndrome: current concepts and future directions
Zampaglione, L., Ferrari, J., Pedica, F., & Goossens, N. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2021.22 · Cited by 9
Eshraghian, A., Moasser, E., Azarpira, N., Fattahi, M. R., Nikeghbalian, S., Malek‐Hosseini, S. A., & Geramizadeh, B. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-02041-8 · Cited by 7
“TM6SF2 rs58542926 T allele and TT genotype are well known genetic risk factors for NAFLD, non-alcoholic steatohepatitis (NASH) and liver cirrhosis [20, 21].”
BackgroundMolecular mechanisms of liver carcinogenesis related to metabolic syndrome
Campani, C., & Nault, J. (2022) · Hepatoma Research · doi:10.20517/2394-5079.2021.126 · Cited by 9
Mungamuri, S. K., Gupta, Y. K., Rao, P. N., & Ravishankar, B. (2023) · Gene Expression · doi:10.14218/ge.2022.00014 · Cited by 11
Újabb adatok a nem alkoholos zsírmáj patogeneziséhez
Pár, A., & Pár, G. (2017) · Orvosi Hetilap · doi:10.1556/650.2017.30775 · Cited by 14
“[44] Liu YL, Reeves HL, Burt AD, et al.”
BackgroundKoeckerling, D., Tomlinson, J., & Cobbold, J. (2020) · Endocrine Connections · doi:10.1530/ec-20-0174 · Cited by 8
Machado, M. V. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2020.90 · Cited by 12
“A variant of TM6SF2, rs58542926 C>T, possesses a substitution of glutamate for lysine at position 167 (E167K), and is a loss-of-function variant that increases the risk of NAFLD and hepatocellular carcinoma, albeit decreasing circulating lipids and protecting from cardiovascular disease([121-125]).”
BackgroundThe practical utility of non-invasive indices in metabolic hepatic steatosis
Sánchez, C. N. T., Durá-Gil, M., del Río, A. A. D., Pérez, C. M. H., Cuadrado, N. M., de la Cuesta, S. G., Martín, D. P., de Luis, D. A., & de la Fuente, R. A. (2022) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2022.06.009 · Cited by 8
Nonalcoholic Fatty Liver Disease
Day, C. P., & Anstee, Q. M. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1562941 · Cited by 7
Self-citationAiello, C., Felli, É., Musarra, T., Nevi, L., Altomare, A., Gracia‐Sancho, J., Baiocchini, A., & Carotti, S. (2025) · International Journal of Cancer · doi:10.1002/ijc.70047 · Cited by 8
“25,26 Similarly, MBOAT7, the rs641738 C>T variant, is associated with reduced hepatic MBOAT7 expression, leading to altered phospholipid composition, increased hepatic fat accumulation, and heightened ER stress.”
EASL position paper on preclinical models of steatotic liver disease
Gallage, S., Castro, R. E., Estall, J. L., Tabas, I. A., Anstee, Q. M., TINIAKOS, D. G., Szabó, G., Yu, J., Desdouets, C., Tacke, F., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.04.029 · Cited by 8
Self-citationChen, V. L., & Brady, G. F. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000618 · Cited by 11
Epidemiological and Genetic Aspects of NAFLD and NASH in Mexico
Vidal‐Cevallos, P., Torre, A., Méndez‐Sánchez, N., Uribe, M., & Chávez-Tapia, N. C. (2022) · Clinical Liver Disease · doi:10.1002/cld.1167 · Cited by 7
Lanzaro, F., Guarino, S., D’Addio, E., Salvatori, A., D’Anna, J. A., Marzuillo, P., del Giudice, E. M., & Sessa, A. D. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i6.1087 · Cited by 5
Alsaif, F. K., Al-hamoudi, W., Alotaiby, M., Alsadoon, A., Almayouf, M., Almadany, H., Abuhaimed, J. M., Ghufran, N., Merajuddin, A., & Khan, I. A. (2022) · Metabolites · doi:10.3390/metabo12121240 · Cited by 6
Semmler, G., Balcar, L., Wernly, S., Datz, L., Semmler, M., Rosenstatter, L., Stickel, F., Aigner, E. S., Wernly, B., & Datz, C. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02196-2 · Cited by 7
Ryaboshapkina, M., & Azzu, V. (2023) · Scientific Reports · doi:10.1038/s41598-023-36187-0 · Cited by 10
“A combination of followup biopsy analysis and cross-sectional studies indicate that weight gain [13], metabolic co-morbidities such as diabetes [13, 14, 17, 19]and at-risk genotypes, for example in PNPLA3, TM6SF2, MBOAT7 [20, 21] place patients at higher risk of NAFLD fibrosis progression.”
BackgroundBódis, K. B., Bombrich, M., Schön, M., Knebel, B., Zaharia, O., Bönhof, G. J., Karusheva, Y., Straßburger, K., Kupriyanova, Y., Kotzka, J., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.06.004 · Cited by 8
Xie, J., Gao, H., Liu, C., Pan, Y., Xu, C., & Xu, L. (2023) · Hepatology Research · doi:10.1111/hepr.13980 · Cited by 6
Causal effects of non-alcoholic fatty liver disease on osteoporosis: a Mendelian randomization study
Zhou, Y., Ni, Y., Wang, Z., Prud’homme, G. J., & Wang, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1283739 · Cited by 8
Newberry, E. P., Molitor, E. A., Liu, A., Chong, K., Liu, X., Alonso, C., Mato, J. M., & Davidson, N. O. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.02.005 · Cited by 6
Wang, C., Liu, S., Lu, L., Liao, S., Yue, H., Dong, Q., Xin, Y., & Xuan, S. (2018) · Hepatitis Monthly · doi:10.5812/hepatmon.66149 · Cited by 6
“NAFLD is defined as the increased hepatic triglyceride content (HTGC) without the consumption of alcohol (1).”
BackgroundHígado graso (parte 1): aspectos generales, epidemiología, fisiopatología e historia natural
Ortíz, J. E. P., Luque, C. B. S., & Quiróz, R. J. O. (2022) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.952 · Cited by 15
947 Shared Genetic Effects Between Hepatic Steatosis and Fibrosis: A Prospective Twin Study
Cui, J. Y., Chen, C., Lo, M., Schork, N. J., Bettencourt, R., Bhatt, A., Hooker, J. C., Nelson, K. E., Long, M. T., Brenner, D. A., et al. (2016) · Gastroenterology · doi:10.1016/s0016-5085(16)33560-0 · Cited by 6
What Is the Optimal Dietary Composition for NAFLD?
George, E. S., Tierney, A. C., Campbell, K. L., Macdonald, G. A., & Hickman, I. J. (2017) · Current Hepatology Reports · doi:10.1007/s11901-017-0373-7 · Cited by 6
Hepatocellular Carcinoma Risk Stratification by Genetic Profiling in Patients with Cirrhosis
Fujiwara, N., & Hoshida, Y. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1681031 · Cited by 6
Lee, H. A. (2024) · Ewha Medical Journal · doi:10.12771/emj.2024.e65 · Cited by 7
“This variant is linked to a 1.6-fold increased risk of MASH and a 1.9-fold higher risk of MASH HCC [80].”
InfluentialLee, Y., & Lee, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-30518-z · Cited by 7
“Previous studies have suggested that specific genetic variants, such as PNPLA3 and TM6SF2, may exacerbate disease severity in patients with advanced fibrosis, potentially accelerating liver injury progression in this subgroup 27,28 .”
Fu, B., Pazokitoroudi, A., Shi, Z., Kar, A., Xue, A., Anand, A., Anand, P., Liu, Z., Border, R., Pajukanta, P., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02411-y · Cited by 17
“We selected rs58542926, a missense variant in the gene TM6SF2 , that has been shown to be associated with ALT and liver disease 48 .”
Zhang, W., Li, M.-Y., Li, Z., Diao, Y., Liu, X.-K., Guo, H.-W., Wu, X.-C., Wang, H., Wang, S., Zhou, Y.-H., et al. (2024) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2024.07.089 · Cited by 5
Misceo, D., Mocciaro, G., D’Amore, S., & Vacca, M. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00871-3 · Cited by 7
Immunometabolic factors contributing to obesity-linked hepatocellular carcinoma
Akl, M. G., & Widenmaier, S. B. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1089124 · Cited by 9
Liu, J., Qi, W., Wang, S., Zhang, Y., Wang, X., Sun, D., Xu, Y., Shi, J., Duan, H., Zhang, Q., et al. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01858-4 · Cited by 7
The Growing Landscape of NAFLD-Associated Hepatocellular Carcinoma and Its Impact in Surveillance
Machado, M. V. (2023) · GE Portuguese Journal of Gastroenterology · doi:10.1159/000531397 · Cited by 5
NASH/NAFLD-Related Hepatocellular Carcinoma: An Added Burden
Georgescu, D., Lighezan, D., Rosca, C. I., Nistor, D., Ancusa, O., Suceava, I., Iancu, M. A., & Kundnani, N. R. (2023) · Life · doi:10.3390/life14010025 · Cited by 6
Are we ready for genetic testing in metabolic dysfunction‐associated steatotic liver disease?
Tulone, A., Pennisi, G., Ciccioli, C., Infantino, G., Mantia, C. L., Cannella, R., Mercurio, F., & Petta, S. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12556 · Cited by 4
Piciotti, R., Longo, M., Agresta, A., Paolini, E., Cespiati, A., Meroni, M., & Dongiovanni, P. (2022) · Hepatoma Research · doi:10.20517/2394-5079.2022.46 · Cited by 9
Gui, Z., Li, W., Fei, S., Guo, M., Chen, H., Sun, L. Y., Han, Z., Tao, J., Ju, X., Yang, H., et al. (2019) · Annals of Transplantation · doi:10.12659/aot.917767 · Cited by 5
Meroni, M., Longo, M., & Dongiovanni, P. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00015 · Cited by 5
“Overwhelming data supported that TM6SF2 loss-of-function affects lipid metabolism and predisposed to hepatic steatosis development and progressive liver injury [79, 81, 82, 91, 92].”
BackgroundClinical Epidemiology of NAFLD
Kim, D., Siddique, O., Perumpail, B. J., & Ahmed, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-94355-8_14 · Cited by 5
Dai, M., Li, Y., Zhang, J., Ruan, Y., Liu, Y., Hao, J., Ji, F., & Yan, X. (2025) · Human Genomics · doi:10.1186/s40246-025-00834-6 · Cited by 5
“Furthermore, our study showed the TM6SF2 rs58542926 "C/T" genotype increases MASLD and MASLD with obesity risk, consistent with most previous studies [40, 41].”
Self-citationZhang, Z., Lu, J., Chen, M., Dai, L., Xiang, Y., Liu, Z., Cao, Y., Sheng, W., Li, C., Song, D., et al. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02784-3 · Cited by 7
MASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues
Ha, S., Zhang, X., Lan-juan, L., & Yu, J. (2026) · 中国科学通报:英文版 · doi:10.1016/j.scib.2026.04.048 · Cited by 8
Li, R., Su, K., Wu, T., Xu, L., Song, W., Sun, D., Zeng, T., Chen, J., Xin, H., Li, Y., et al. (2025) · BMC Genomics · doi:10.1186/s12864-025-11668-w · Cited by 4
“…development: rs738409 (patatin-like phospholipase domain-containing 3, PNPLA3 ) [15, 16], rs58542926 (transmembrane 6 superfamily member 2, TM6SF2 ) [17–19], rs641738 (membrane-bound O-acyltransferase domain containing 7, MBOAT7 ) [20, 21], and rs1260326 (glucokinase regulator, GCKR ) [22, 23].”
Li, T., Cui, Y., Li, T., Xiang, Q., Chen, Y., Zheng, X., Peng, J., & Tang, Z. (2023) · Experimental Cell Research · doi:10.1016/j.yexcr.2023.113666 · Cited by 6
Microbiome and Genetic Factors in the Pathogenesis of Liver Diseases
Miteva, D., Peshevska-Sekulovska, M., Snegarova, V., Peruhova, M., Vasilev, G., Vasilev, G., Sekulovski, M., Lazova, S., Gulinac, M., Tomov, L., et al. (2023) · Gastroenterology Insights · doi:10.3390/gastroent14040041 · Cited by 6
Habib, S. (2024) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v15.i4.93606 · Cited by 8
A fatty liver leads to a broken heart?
Adams, L. A., & Anstee, Q. M. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.03.012 · Cited by 4
Self-citationDesjonqueres, E., & Gigante, E. (2022) · Hepatoma Research · doi:10.20517/2394-5079.2021.136 · Cited by 4
TM6SF2 as a genetic risk factor for fibrosis
Daly, A. K., Day, C. P., Liu, Y., & Anstee, Q. M. (2014) · Hepatology · doi:10.1002/hep.27656 · Cited by 6
“Importantly, our main analysis demonstrating increased risk of NAFLD fibrosis for rs58542926 involved direct comparison of fibrosis stages within a histologically characterized NAFLD cohort without recourse to population controls.(2) This eliminated interference from controls with undiagnosed NAFLD, unlike the Sookoia…”
BackgroundResultSelf-citationLiu, Z., Zhang, Y., Graham, S., Pique-Regi, R., Dong, X. C., Chen, Y. E., Willer, C., & Liu, W. (2019) · doi:10.1101/657734 · Cited by 250
TM6SF2 in Hepatic Lipid Metabolism and Chronic Liver Disease
Al-Nakeb, M., & Haep, N. (2026) · Livers · doi:10.3390/livers6020017 · Cited by 3
Monogenic and Polygenic Risk in Common Liver Diseases: Implications for Clinical Care
Ajmera, V. H., Huang, D. Q., Chen, V. L., & Reddy, K. R. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.03.020 · Cited by 5
Samarasinghe, S. M., Hewage, A. S., Siriwardana, R. C., Tennekoon, K. H., Niriella, M. A., Silva, S. D., & Abeysuriya, V. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03738-w · Cited by 3
“…exome-wide association study showed a variant (rs58542926) in the transmembrane 6 superfamily member 2 ( TM6SF2) gene to be associated with higher liver fat levels [13] where several successive studies showed its significant association with NAFLD risk [14, 15] and NAFLD-related HCC risk [14, 16].”
Zatta, R., da Silva, L. S., Felga, G. E. G., & Pimentel, C. F. M. G. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i7.107837 · Cited by 3
Grove, J. I., Thiagarajan, P., Astbury, S., Harris, R., Delahooke, T., Guha, I. N., & Aithal, G. P. (2018) · Liver International · doi:10.1111/liv.13733 · Cited by 3
Self-citationDyakonova, A. T., Куртанов, Х. А., Pavlova, N. I., Соловьева, Н. А., Soloveva, Y. A., Филиппова, Н. П., & Александрова, Т. Н. (2019) · Современные проблемы науки и образования · doi:10.17513/spno.29334 · Cited by 4
Non-Alcoholic Fatty Liver Disease as a Coronary Heart Disease Severity Predictor
Ismael, H., Tag‐Adeen, M., Abdelrady, A. M., El‐Shazly, M., & Hussein, A. A. (2020) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2020.114018 · Cited by 3
Maleki, S., Sharafi, H., Honarvar, B., Eslami, M., Lankarani, K. B., & Alavian, S. M. (2022) · Hepatitis Monthly · doi:10.5812/hepatmon-133330 · Cited by 3
“Regarding TM6SF2 rs58542926, the association of the K167E variant with NAFLD and NAFLD-related liver diseases was studied previously (24, 25).”
BackgroundNatural History of Nonalcoholic Fatty Liver Disease
Ismaiel, A., Portincasa, P., & Dumitrascu, D. L. (2023) · Springer eBooks · doi:10.1007/978-3-031-33548-8_3 · Cited by 3
Venu, S., Rajesh, G., Pillai, B. V., Biswas, L., Poojara, R. H., & Raj, M. (2025) · BMJ Paediatrics Open · doi:10.1136/bmjpo-2024-003138 · Cited by 3
Satyam, S. M., El‐Tanani, M., Rabbani, S. A., Aljabali, A. A. A., El‐Tanani, Y., Patoulias, D., & Rizzo, M. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128366825250307043756 · Cited by 4
Chen, H., Yu, X., Wang, X., Huang, J., Wu, J., Zhou, X., Hu, K., & Song, Z. (2025) · European journal of medical research · doi:10.1186/s40001-025-02837-4 · Cited by 3
“…genetic pre-dispositions, including higher carriage rates of TM6SF2 rs58542926 and interferon λ3/4 variants linked to fibrosis severity [38, 39]; (2) metabolic inflexibility, wherein hepatic fat accumulation and pronounced hepatic insulin resistance occur independently of obesity or…”
Cardiovascular risk in pediatric nonalcoholic fatty liver disease: recent advances
Baskar, S., Jhaveri, S., & Alkhouri, N. (2015) · Clinical Lipidology · doi:10.2217/clp.15.26 · Cited by 3
A new classification of diabetes mellitus – current approaches and challenges
Szatko, A., Mordarska, K., Pokrzywa, J., & Godziejewska-Zawada, M. (2020) · Wiedza Medyczna · doi:10.36553/wm.65 · Cited by 3
Metadata
- Authors
- Liu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., Donaldson, P., Aithal, G. P., Francque, S., Van Gaal, L., Clement, K., Ratziu, V., Dufour, J.-F., Day, C. P., Daly, A. K., & Anstee, Q. M.
- Affiliations
- Newcastle University (GB)
- Addenbrooke's Hospital (GB)
- University Hospital of Bern (CH)
- Inserm (FR)
- Nottingham University Hospitals NHS Trust (GB)
- Antwerp University Hospital (BE)
- Pitié-Salpêtrière Hospital (FR)
- Corresponding author
- Anstee, Quentin M.
- ORCID
- Venue
- Nature Communications
- Published
- 2014-06-30
- Volume
- 5
- Issue
- 1
- Pages
- 4309-4309
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4279183
- OpenAlex
- W2038831349
- Cited by
- 623
- References
- 45
- Citations by year
- 2026: 22 · 2025: 42 · 2024: 50 · 2023: 51 · 2022: 56 · 2021: 61 · 2020: 82 · 2019: 49 · 2018: 50 · 2017: 45 · 2016: 54 · 2015: 50 · 2014: 11
- FWCI
- 40.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Open Access CRIS of the University of Bern
- Funders
- National Institute for Health and Care Research (FP7/2007–2013)
- European Commission (2007–2013, FP7 2007-2013, FP7/2007, 241762)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- TM6SF2, rs58542926, non-alcoholic fatty liver disease, liver fibrosis, liver cirrhosis, non-synonymous polymorphisms, genetic association, hepatic triglyceride content, neurocan, chromosome 19, steatohepatitis, PNPLA3, disease progression
- MeSH terms
- Adult, Aged, Alleles, Female, Genotype, Heterozygote, Humans, Liver, Liver Cirrhosis, Male, Membrane Proteins, Middle Aged, Nerve Tissue Proteins, Chondroitin Sulfate Proteoglycans, Cohort Studies, Disease Progression, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Lectins, C-Type, Neurocan, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.